AZN wins the EU nod for Imfinzi in early gastric and GEJ cancers, backed by strong survival data and expanding its ...
AstraZeneca’s Imfinzi in combo with standard-of-care FLOT chemotherapy gets European approval to treat patients with early gastric and gastroesophageal cancers: Cambridge, UK Tu ...
Nuclear Medicine, Kailash Deepak Hospital, explains why time is the most critical variable in cancer care. In this ...
Johnson & Johnson JNJ reported positive results from an early-stage study evaluating its investigational intravesical ...
EAU 2026: Preliminary Results of a Phase II Study to Evaluate the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) in ...
Dr. Liangyou concluded his presentation discussing the efficacy and safety of disitamab vedotin combined with tislelizumab as adjuvant therapy after radical surgery for patients with HER2-expression ...
Image in Creative Commons. In 1967, Hungarian scientist Endre Mester tried to cure skin cancer in mice using a low-powered ...
Metabolites in tissue fluid offer important clues that could help predict infection risk among women who undergo breast ...
Drs Uzzo, Chung, and Croll of Fox Chase Cancer Center at Temple University Health discuss top presentations from the ASCO Genitourinary Cancers Symposium 2026. The American Society of Clinical ...
Co-occurring alterations in EGFR-mutant NSCLC are increasingly detected via broad NGS and may signal aggressive biology, ...
As an employee of Henry Ford Health for more than 20 years, Brooke Wessman focused on health care process improvement in ...
KEYNOTE-B15 compared perioperative enfortumab vedotin plus pembrolizumab against neoadjuvant cisplatin-based chemotherapy in cisplatin-eligible MIBC, using event-free survival as the primary endpoint.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results